Naturally occurring phytoestrogen, found in soy products.
- TR 545: Genistein (CASNR 446-72-0)—2-year Bioassay. Naturally occurring phytoestrogen, found in soy products.
- TR 543: \( \alpha \)-Methylstereone (CASNR 98-83-9).
- Used in the production of resins and polymers.
- TR 540: Methylene blue trihydrate (CAS No. 7220-79-3).
- Dye used to stain tissues and bacteriological samples for microscopy and an antidote for methemoglobinemia; previously used as a hair colorant.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: National Institute for Occupational Safety and Health (NIOSH) Support for Conferences and Scientific Meetings, Request for Applications PAR 06-014

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): NIOSH Support for Conferences and Scientific Meetings, Request for Applications PAR 06-014.

Time and Date: 1 p.m.–4 p.m., March 29, 2006 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552(b)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management, Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to NIOSH Support for Conferences and Scientific Meetings, Request for Applications PAR 06-014.

For More Information Contact: George Bockos, MS, Scientific Review Administrator. National Institute for Occupational Safety and Health, CDC, 626 Cochran Mill Road, MS PO-5, Pittsburgh, PA 15236, Telephone 412-396-6465. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Injury Prevention and Control Initial Review Group

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: National Center for Injury Prevention and Control (NCIPC) Initial Review Group (IRG).

Times and Dates: 6:30 p.m.–10 p.m., April 10, 2006, 8:30 a.m.–6 p.m., April 11, 2006, 8 a.m.–5:30 p.m., April 12, 2006.

Place: Hilton Atlanta Airport and Towers, 1031 Virginia Avenue, Atlanta, Georgia 30354.

Status: Open: 6:30 p.m.–7:15 p.m., April 10, 2006. Closed: 7:15 p.m. to 10 p.m., April 10, 2006, 8:30 a.m. to 6 p.m., April 11, 2006, 8 a.m. to 5:30 p.m., April 12, 2006.

Purpose: This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS) and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including state and local government agencies, to conduct specific injury research that focuses on injury prevention and control.

Matters to Be Discussed: Agenda items include an overview of the injury program, discussion of the review process and panelists responsibilities, and the review of, and vote on, applications. Beginning at 7:15 p.m., April 10, through 5:30 p.m., April 12, the Group will review individual research grant and cooperative agreement applications submitted in response to Fiscal Year 2006 Requests for Applications (RFAs) related to the following individual research announcements: #06001, Research Grants to Prevent Unintentional Injuries; #06002, Dissertation Grant Awards for Violence-Related Injury Prevention Research in Minority Communities; #06003, Research Grants to Describe Traumatic Brain Injury Consequences; #06004, Grants for Violence-Related Injury Prevention Research: Youth Violence, Suicidal Behavior, Child Maltreatment, Intimate Partner Violence, and Sexual Violence; #06005, Research Grants for the Care of the Acutely Injured; #06007, Evaluation of Community-based Approaches to Increasing Seat Belt Use Among Adolescent Drivers and Their Passengers.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health Advisory Board on Radiation and Worker Health

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Advisory Board on Radiation and Worker Health (ABRWH), National Institute for Occupational Safety and Health (NIOSH).

Time and Date: 10 a.m.–4 p.m., EST, Tuesday, March 14, 2006.

Place: Audio Conference Call via FTS Conferencing. The USA toll free dial in number is 1–866–643–6504, pass code of 944850.

Status: Open to the public, but without a public comment period.

Background: The ABRWH was established under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA) of 2000 to advise the President, delegated to the Secretary of Health and Human Services (HHS), on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Board include providing advice on the development of probability of causation guidelines which have been promulgated by HHS as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose...
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the NIH Advisory Board for Clinical Research.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: NIH Advisory Board for Clinical Research.
Date: March 24, 2006.
Time: 10 a.m. to 2 p.m.
Agenda: To review proposed 2007 Clinical Center budget.
Place: National Institutes of Health, Building 10, 10 Center Drive, 4–2551, CRC Medical Board Room, Bethesda, MD 20892.
Contact Person: Maureen E. Gormley, Executive Secretary, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Building 10, Room 6–2551, Bethesda, MD 20892, 301/496–2897.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group; Subcommittee D—Clinical Studies.
Date: April 9–10, 2006.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
Contact Person: Peter J. Wirth, PhD.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group; Subcommittee D—Clinical Studies.
Date: March 16, 2006.
Time: 8 a.m. to 5 p.m.